"Austin Clinical Research conducts clinical trials evaluating drug therapies and drug delivery devices for a variety of eye diseases including age-related macular degeneration, diabetic retinopathy, retinal vein occlusions and uveitis. We also collaborate with other local research sites to perform retinal exams for clinical trials evaluating systemic medications. We strive to ensure that every patient is an optimal fit for a particular clinical trial and afforded unique, individualized care."

During the past decade, Retina Research Center conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 29 clinical trials were completed, i.e. on average, 69% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 21 clinical trials were completed. i.e. 116.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Research Center" #1 sponsor was "Jaeb Center for Health Research" with 21 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "ThromboGenics" with 3 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Research Center" #1 collaborator was "National Eye Institute (NEI)" with 19 trials as a collaborator, "National Institutes of Health (NIH)" with 8 trials as a collaborator, "Genentech, Inc." with 6 trials as a collaborator, "Allergan" with 4 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 4 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Retina Research Center" are "Diabetic Macular Edema" (19 trials), "Diabetic Retinopathy" (14 trials), "Macular Degeneration" (5 trials), "Geographic Atrophy" (4 trials) and "Proliferative Diabetic Retinopathy" (4 trials). Many other conditions were trialed in "Retina Research Center" in a lesser frequency.

Most popular intervention types in "Retina Research Center" are "Drug" (54 trials), "Other" (10 trials), "Procedure" (10 trials), "Device" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Ranibizumab" (7 trials), "Sham Procedure" (5 trials), "Aflibercept" (4 trials) and "Faricimab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Retina Research Center" are 69 trials for "All" genders.

Currently, there are NaN active trials in "Retina Research Center". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 45 completed trials in Retina Research Center, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Research Center, 9 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".